文献速递妇产影像儿科影像US

妊娠合并胎盘绒毛膜血管瘤的围产结局:系统综述与Meta分析

Perinatal outcome of pregnancies complicated by placental chorioangioma: systematic review and meta-analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2020-01-01

该系统综述与Meta分析纳入28项研究共161例产前超声诊断胎盘绒毛膜血管瘤的单胎妊娠,评估围产期结局。未干预者宫内死亡8.2%、围产期死亡11.1%,小于胎龄儿24.0%、早产<37周34.1%。肿瘤大小和胎儿水肿可能是围产结局的主要决定因素。

要点

  • 产前超声诊断胎盘绒毛膜血管瘤与不良围产结局相关,未干预者围产期死亡率11.1%。
  • 肿瘤越大,多数不良结局的发生率呈进行性升高。
  • 合并胎儿水肿者不良围产结局的发生率高。

核心结论

  • 胎盘绒毛膜血管瘤与不良围产结局相关,肿瘤大小和胎儿水肿可能是受累妊娠围产结局的主要决定因素。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE、CINAHL和ClinicalTrials.gov数据库,纳入28项研究共161例产前超声诊断胎盘绒毛膜血管瘤且不伴其他结构异常的单胎妊娠,采用随机效应模型对比例进行Meta分析。

关键影像表现/征象

  • 产前超声可见胎儿高动力循环征象者占21.0%(95%CI 9.6-35.3%)。
  • 胎儿大脑中动脉收缩期峰值流速升高者占20.6%(95%CI 10.9-32.3%)。
  • 产前超声可检出胎儿水肿、贫血、羊水过多、高动力循环征象及小于胎龄儿等相关非结构异常。

诊断标准与关键数值

  • 未干预的绒毛膜血管瘤妊娠中,宫内死亡8.2%(95%CI 3.8-15.0%)。
  • 未干预者新生儿死亡3.8%(95%CI 1.0-8.1%),围产期死亡11.1%(95%CI 5.0-19.4%)。
  • 出生时小于胎龄儿24.0%(95%CI 13.5-36.5%),早产<37周34.1%(95%CI 21.1-48.3%)。
  • 新生儿复合发病率12.0%(95%CI 4.5-22.3%)。
  • 接受宫内治疗的胎儿围产期死亡率31.2%(95%CI 18.1-46.1%),57.3%(95%CI 39.2-74.4%)在水肿或高动力循环缓解后治疗。

临床应用与阅片要点

  • 产前超声诊断胎盘绒毛膜血管瘤时,应评估肿瘤大小及有无胎儿水肿、高动力循环征象。
  • 存在胎儿水肿或高动力循环征象时,目前无随机对照试验比较干预与期待治疗。
  • 作者结论提示肿瘤大小和胎儿水肿可能是围产结局的主要决定因素。

局限性

  • 无随机对照试验比较干预与期待治疗在伴胎儿受损征象(水肿或高动力循环)的绒毛膜血管瘤妊娠中的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To report the perinatal outcome of singleton pregnancies complicated by placental chorioangioma diagnosed on prenatal ultrasound.

METHODS: MEDLINE, EMBASE, CINAHL and ClinicalTrials.gov databases were searched for studies reporting the outcome of pregnancies complicated by placental chorioangioma. Inclusion criteria were singleton pregnancy diagnosed with placental chorioangioma on prenatal ultrasound, with no other associated structural anomaly. The primary outcome was perinatal mortality. Secondary outcomes included associated non-structural anomalies detected on prenatal ultrasound (including fetal hydrops, anemia, polyhydramnios, signs of hyperdynamic circulation and small-for-gestational-age (SGA) fetus), SGA at birth, composite neonatal morbidity and preterm birth. Outcome was assessed separately in pregnancies undergoing and those not undergoing fetal therapy. Subanalyses were performed according to the presence of hydrops and the size of the tumor in all pregnancies diagnosed with chorioangioma. Random-effects meta-analyses of proportions were used to analyze the data.

RESULTS: Twenty-eight studies (161 pregnancies) were included. In pregnancies complicated by chorioangioma that did not undergo intervention, intrauterine death occurred in 8.2% (95% CI, 3.8-15.0%), while neonatal death and perinatal death occurred in 3.8% (95% CI, 1.0-8.1%) and 11.1% (95% CI, 5.0-19.4%), respectively. SGA at birth was present in 24.0% (95% CI, 13.5-36.5%) of cases, while preterm birth < 37 weeks complicated 34.1% (95% CI, 21.1-48.3%) of pregnancies. Composite neonatal morbidity occurred in 12.0% (95% CI, 4.5-22.3%) of cases. On ultrasound, signs of fetal hyperdynamic circulation were present in 21.0% (95% CI, 9.6-35.3%) of cases, while peak systolic velocity in the fetal middle cerebral artery was increased in 20.6% (95% CI, 10.9-32.3%). Subanalysis according to the size of chorioangioma, including both pregnancies that did and those that did not undergo intervention, showed a progressive increase in the occurrence of most of the outcomes explored with increasing size of the tumor. Furthermore, the prevalence of adverse perinatal outcome was high in pregnancies complicated by chorioangioma presenting with fetal hydrops. There was no randomized controlled trial comparing intervention vs expectant management in pregnancies complicated by chorioangioma with signs of fetal compromise (hydrops or hyperdynamic circulation). Overall, perinatal mortality occurred in 31.2% (95% CI, 18.1-46.1%) of fetuses undergoing in-utero therapy, and 57.3% (95% CI, 39.2-74.4%) had resolution of hydrops or hyperdynamic circulation after treatment.

CONCLUSIONS: Placental chorioangioma is associated with adverse perinatal outcome. The size of the mass and presence of fetal hydrops are likely to be the main determinants of perinatal outcome in affected pregnancies. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Buca D, Iacovella C, Khalil A, et al. Perinatal outcome of pregnancies complicated by placental chorioangioma: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2020. PMID: 31034661. doi:10.1002/uog.20304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。